IDEXX Laboratories, Inc.
NASDAQ•IDXX
CEO: Mr. Jonathan J. Mazelsky
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1991-06-21
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Contact Information
Market Cap
$57.12B
P/E (TTM)
55.8
26.9
Dividend Yield
--
52W High
$769.98
52W Low
$356.14
52W Range
Rank17Top 4.2%
6.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$1.11B+13.30%
4-Quarter Trend
EPS
$3.43+21.20%
4-Quarter Trend
FCF
$371.23M+93.36%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Total Revenue Growth Strong Total revenue reached $3.213 B USD for nine months, reporting 9.2% growth; organic revenue grew 8.7% compared to prior year.
Operating Income Surges Income from operations increased $177.775 M USD to $1.044 B USD, reflecting 20.5% growth for the nine months ended September 30.
Gross Margin Expansion Noted Total gross profit margin improved 90 basis points to 62.3% driven by recurring revenue volume and pricing benefits offsetting costs.
Operating Cash Flow Rises Cash provided by operating activities was $826.045 M USD, a $159.069 M USD increase year-to-date period compared to 2024.
Risk Factors
Foreign Currency Headwinds Persist Strengthening U.S. dollar negatively impacts international revenue growth rates; projected to reduce revenue by $4 M USD remainder of 2025.
Litigation Settlement Paid Company paid $80 M USD judgment in April 2025 to conclude 2018 breach of contract royalty lawsuit; payment impacted cash flow.
Inflationary Cost Pressures Expect continued higher costs for labor, commodities, and transportation; may not fully offset these increases via productivity or pricing.
Tariff and Trade Uncertainty Changes in global tariff and trade policies create volatility and uncertainty, potentially reducing demand for products and services globally.
Outlook
Strong Liquidity Position Net debt to Adjusted EBITDA ratio stands at 0.51, well below 3.5-to-1 covenant; $793.2 M USD availability remains under Credit Facility.
Tax Law Accelerates Deductions Acceleration of R&D deductions due to OBBBA expected to reduce projected 2025 income taxes due by approximately $105 M USD.
Debt Maturity Management Anticipate paying off $75.0 M USD 2025 Series B Notes in December 2025 using cash or Credit Facility borrowings as planned.
Capital Spending Planned Total capital expenditure plan for 2025 estimated at $140.0 M USD, focusing on manufacturing facilities and customer-facing software development.
Peer Comparison
Revenue (TTM)
$321.33B
TAK$29.67B
BDX$21.84B
Gross Margin (Latest Quarter)
88.3%
77.9%
VEEV75.4%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| COR | $68.84B | 44.3 | 131.5% | 10.0% |
| BDX | $59.11B | 35.4 | 6.6% | 34.7% |
| IDXX | $57.12B | 55.8 | 67.8% | 32.9% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.0%
Steady Growth
4Q Net Income CAGR
8.3%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Feb 2, 2026
EPS:$2.93
|Revenue:$1.07B
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 3, 2025|Revenue: $1.11B+13.3%|EPS: $3.43+21.2%BeatForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 4, 2025|Revenue: $1.11B+10.5%|EPS: $3.66+48.8%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 1, 2025|Revenue: $998.43M+3.6%|EPS: $2.98+4.9%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 21, 2025|Revenue: $3.90B+6.5%|EPS: $10.77+5.9%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Oct 31, 2024|Revenue: $975.54M+6.6%|EPS: $2.83+11.0%BeatForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 6, 2024|Revenue: $1.00B+6.4%|EPS: $2.46-8.9%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 1, 2024|Revenue: $964.10M+7.1%|EPS: $2.84+10.1%BeatForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 22, 2024|Revenue: $3.66B+8.7%|EPS: $10.17+25.2%Beat